Latest Breaking News On - Hepalys pharma inc - Page 4 : comparemela.com

Inventiva reports its 2023 first-half financial results and provides a corporate update

Inventiva reports its 2023 first-half financial results and provides a corporate update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesNew yorkSouth koreaHepalys pharmaAude lepreuxSino biopharmCatalys pacificPascaline clercCompany natiUniversity of floridaExchange commissionMarket programData monitoring committeeEuropean investment bankEuropean parliament

Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaNew yorkUnited statesSan franciscoSouth koreanSouth koreansCatalys pacificHepalys pharmaAude lepreuxNonliver comorbiditiesPascaline clercExchange commission onMitsubishi ufjInnovation fundHepalys pharma inc weGlobal external affairs

Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea - Inventiva (OTC:IVEVF), Inventiva (NASDAQ:IVA)

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is

South koreaSan franciscoUnited statesNew yorkSouth koreanSouth koreansNonliver comorbiditiesHepalys pharmaCatalys pacificMitsubishi ufjHepalys pharma incExchange commission onInnovation fundHepalys pharma inc weLong island cityGreater china

INVENTIVA: Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

INVENTIVA: Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesNew yorkSan franciscoBaden wübergSouth koreansSouth koreanNonliver comorbiditiesPascaline clercAude lepreuxCatalys pacificHepalys pharmaExchange commission onHepalys pharma incInnovation fundMitsubishi ufj

Inventiva and Hepalys Pharma, Inc announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea -September 20, 2023 at 04:01 pm EDT

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million.

United statesNew yorkSan franciscoSouth koreaSouth koreansSouth koreanAude lepreuxCatalys pacificNonliver comorbiditiesHepalys pharmaPascaline clercHepalys pharma incGlobal external affairsExchange commission onBrunswick groupMitsubishi ufj